ArticleVaccines2023

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study.

Dejan Jakimovski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.